Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas

Glioma Clinical Trial

Official title:

Role of Ga-68 Prostate Specific Membrane Antigen PET/CT in Detection of Recurrence in Patients With Gliomas

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06241391
• Other study ID #: T/IMF/21/22/04
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 2024
• Est. completion date: February 2025

Study information

• Verified date: February 2024
• Source: All India Institute of Medical Sciences, Bhubaneswar
• Contact: Dr.Girish Kumar Parida, MD
• Phone: +91 9968856817
• Email: grissh135[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids analogues. Among these, 18F-FDG is the most commonly used tracer due to its broader use and easy availability. However, high physiological uptake in the brain is a significant limitation. The main limitation of other tracers is the need for onsite cyclotrons for their production, making their availability difficult. So, the search for an ideal modality is still ongoing, and the latest addition to this search is a radio ligand labeled Prostate Specific Membrane Antigen (PSMA). It is a new but potentially promising radiotracer, currently showing its utility in different malignancies. Investigators, therefore, aim to identify whether Ga-68 PSMA PET-CT has better diagnostic accuracy in the detection of recurrent gliomas than conventional imaging modalities.

Description:

Prostate Specific Membrane Antigen (PSMA is a type II membrane glycoprotein and is typically overexpressed in primary and metastatic lesions of prostate malignancy as the name suggests. However, this overexpression is not limited to prostate cancer only. It has been reported that, PSMA is overtly expressed in the vascular endothelium of various other malignancies where significant neovascularization is seen. Gliomas being highly vascularized tumors, have shown significant PSMA expression in their vascular endothelium especially in high grade ones. If this PSMA expression can be assessed through noninvasive molecular imaging, this would further ease the management these tumors. Different lesions have shown different grades of PSMA uptake in the PET/CT with high grade gliomas showing high uptake. Most of the articles published till date are either case reports or studies comprising very few numbers of patients. We would like to use the PET tracer Ga -68 PSMA for the detection of recurrence in patients with glioma. Investigators believe that 68 Ga PSMA PET-CT has the potential to play an imperative role in noninvasively evaluating recurrent gliomas and can overcome the limitations of the currently used modalities. Besides, extrapolation of the PSMA expression, which is indirect evidence of neovascularization, can also be used to assess treatment options like VEGF inhibitors (Bevacizumab). These studies can also pave the way for further studies involving PSMA-based radio ligand therapy, which is currently being successfully applied in patients with metastatic prostate cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 35
• Est. completion date: February 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with age more than18 years.
• Patients having past history of histologically proven glioma.
• Patients who have undergone prior treatment with tumor resection and/or radiation therapy and/or chemotherapy.
• Clinically suspected cases of recurrence.
• Patient should be willing to and able to give written informed consent

Exclusion Criteria:

• Pregnant lady.
• Breastfeeding mother.
• Patients who will deny to give consent.
• Any brain primary other than high grade glioma
• Patient diagnosed with other primary malignancy
• Patient with life threating neurological emergency

Related Conditions & MeSH terms

• Anaplastic Astrocytoma
• Astrocytoma
• Glioblastoma
• Glioblastoma Multiforme
• Glioma
• Oligodendroglioma

Intervention

Diagnostic Test:
• PSMA PET-CT
Prostate Specific Membrane Antigen PET-CT

Locations

Country	Name	City	State
India	All India Institute of Medical Sciences, Bhubaneswar	Bhubaneswar	Odisha

Sponsors (1)

Lead Sponsor	Collaborator
All India Institute of Medical Sciences, Bhubaneswar

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas	Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas	3 months
Secondary	Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images	Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images	3 months
Secondary	Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas	Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas	3 months
Secondary	Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan	Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan	3 months
Secondary	Correlation between PSMA expression in histopathology specimen (using IHC) and SUVmax of recurrent lesion on 68Ga- PSMA PET-CT scan.	Correlation between PSMA expression in histopathology specimen (using IHC) and	3 months